 |
 |
 |
|
Healthcare provider experience of administering long-acting lenacapavir for people with HIV with heavy treatment experience, engaged through a compassionate use program in the United States
|
|
|
IAS 2023 July 25
A.N. Herbst1, J. Fang1, O. Boiko2, M.S. Dunbar3, L. Temme3, K. Dunn3, S. Navadeh3, M. Rhee3, W.R. Lenderking1, B. Gaglio1
1Evidera, Bethesda, United States; 2Evidera, London, United Kingdom; 3Gilead Sciences, Inc., Foster City, CA, USA







|
|
|
 |
 |
|
|